Two-Pronged gene therapy takes on deadly brain tumors

NCT ID NCT07346144

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial tests a new gene therapy called TGX-007 for people with a fast-growing brain cancer called glioblastoma. The therapy uses a harmless virus to deliver two special instructions: one helps a common drug kill cancer cells, and the other wakes up the immune system to attack the tumor. About 68 adults aged 18-70 will receive a single injection of TGX-007 into their tumor, followed by a short course of an antiviral pill, before standard surgery. The study aims to find the safest and most effective dose and to see if it helps people live longer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma malignant glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Ohio State University Hospital

    RECRUITING

    Columbus, Ohio, 43210, United States

    Contact Email: •••••@•••••

    Contact

  • Royal Infirmary of Edinburgh

    RECRUITING

    Edinburgh, United Kingdom

    Contact Email: •••••@•••••

    Contact